Document is current
Any future updates will be listed below
-
Authors
Fuchs, Sebastian P.
Mondragon, Paula G.
Zabizhin, Rachel
Tomer, Shallu https://orcid.org/0000-0003-0462-4315
Wang, Li
Cook, Ethan https://orcid.org/0009-0005-6874-6874
Dudley, Dawn M.
Weisgrau, Kimberly L.
Furlott, Jessica
Coonen, Jennifer
Alexander, Eric
Xie, Jun https://orcid.org/0000-0001-9565-1567
Gao, Guangping https://orcid.org/0000-0003-0097-9012
Termini, James M.
Martinez-Navio, Jose M. https://orcid.org/0000-0003-0560-5407
Zhen, Anjie https://orcid.org/0000-0001-6139-7820
Desrosiers, Ronald C. https://orcid.org/0000-0001-6851-3003
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19AI149646)
Miami-Dade County
- License Information
-
More Information
Article History
Received: 5 May 2025
Accepted: 3 September 2025
First Online: 7 October 2025
Competing interests
: The authors declare no competing interests. G.G. is a scientific co-founder of Voyager Therapeutics, Adrenas Therapeutics, and Aspa Therapeutics, and holds equity in these companies. G.G. is an inventor on patents with potential royalties licensed to Voyager Therapeutics, Aspa Therapeutics, and other biopharmaceutical companies. R.C.D. is a co-founder of Marguron LLC.
